中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.042 seconds)

    Inhibitors of bruton's tyrosine kinase
    1.
    发明授权
    Inhibitors of bruton's tyrosine kinase 有权
    布鲁特酪氨酸激酶抑制剂

    公开(公告)号：US09133134B2

    公开(公告)日：2015-09-15

    申请号：US14401104

    申请日：2013-05-15

    Applicant: Pharmacyclics, Inc.

    Inventor： Wei Chen ,  David J. Loury ,  Tarak D. Mody

    IPC: C07D239/48 ,  A61K31/505

    CPC classification number: C07D239/48 ,  A61K31/505

    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

    Abstract translation: 本文描述的是激酶抑制剂化合物，用于合成这种抑制剂的方法，以及在治疗疾病中使用这些抑制剂的方法。 本文进一步描述了用于测定包括激酶在内的蛋白质的适当抑制剂的方法，测定和系统。

    Pyrrolopyrimidine compounds as kinase inhibitors
    2.
    发明授权
    Pyrrolopyrimidine compounds as kinase inhibitors 有权
    吡咯并嘧啶化合物作为激酶抑制剂

    公开(公告)号：US09096604B2

    公开(公告)日：2015-08-04

    申请号：US14081053

    申请日：2013-11-15

    Applicant: Pharmacyclics, Inc.

    Inventor： Wei Chen ,  David J. Loury ,  Longcheng Wang

    IPC: A01N43/90 ,  A61K31/519 ,  C07D487/00 ,  C07D487/04

    CPC classification number: C07D487/04 ,  A61K31/519

    Abstract: Disclosed herein are compounds exemplified by the following structure Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds of Formula (I). Methods of using the Btk inhibitors exemplified by the structure of Formula (I) are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    Abstract translation: 本文公开了通过与布鲁特酪氨酸激酶（Btk）形成共价键的以下结构式（I）示例的化合物。 还公开了包含式（I）化合物的药物组合物。 公开了单独或与其它治疗剂组合用于治疗自身免疫性疾病或病症，异种免疫性疾病或病症，包括淋巴瘤和炎性疾病在内的癌症的公式（I）结构所使用的Btk抑制剂的方法或 条件。

    PURINONE COMPOUNDS AS KINASE INHIBITORS
    6.
    发明申请
    PURINONE COMPOUNDS AS KINASE INHIBITORS 有权
    嘌呤化合物作为激酶抑制剂

    公开(公告)号：US20140378446A1

    公开(公告)日：2014-12-25

    申请号：US14375765

    申请日：2013-01-30

    Applicant: Pharmacyclics, Inc.

    Inventor： Wei Chen ,  David J. Loury ,  Yan Shunqi ,  Longcheng Wang ,  Leah Lynn Frye

    IPC: C07D473/34

    CPC classification number: C07D473/34

    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    Abstract translation: 本文公开了与布鲁顿酪氨酸激酶（Btk）形成共价键的化合物。 还描述了Btk的不可逆抑制剂。 此外，还描述了Btk的可逆抑制剂。 还公开了包含化合物的药物组合物。 公开了使用Btk抑制剂的方法，单独或与其它治疗剂组合用于治疗自身免疫性疾病或病症，异种免疫疾病或病症，癌症，包括淋巴瘤和炎性疾病或病症。

    Pyrrolopyrimidine compounds as kinase inhibitors
    8.
    发明授权
    Pyrrolopyrimidine compounds as kinase inhibitors 有权

    公开(公告)号：US09062058B2

    公开(公告)日：2015-06-23

    申请号：US14081053

    申请日：2013-11-15

    Applicant: Pharmacyclics, Inc.

    Inventor： Wei Chen ,  David J. Loury ,  Longcheng Wang

    IPC: A01N43/90 ,  A61K31/519 ,  C07D487/00 ,  C07D487/04

    Abstract: Disclosed herein are compounds exemplified by the following structure Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds of Formula (I). Methods of using the Btk inhibitors exemplified by the structure of Formula (I) are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    PYRAZOLO[3,4-d]PYRIMIDINE AND PYRAZOLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
    9.
    发明申请
    PYRAZOLO[3,4-d]PYRIMIDINE AND PYRAZOLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS 有权
    吡唑并[3,4-d]吡嗪和吡唑并[2,3-d]吡嗪化合物作为激酶抑制剂

    公开(公告)号：US20150018336A1

    公开(公告)日：2015-01-15

    申请号：US14369998

    申请日：2012-12-28

    Applicant: Pharmacyclics, Inc.

    Inventor： Wei Chen ,  David J. Loury

    IPC: C07D487/04

    CPC classification number: C07D487/04

    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    Abstract translation: 本文公开了与布鲁顿酪氨酸激酶（Btk）形成共价键的化合物。 还描述了Btk的不可逆抑制剂。 公开了制备化合物的方法。 还公开了包含化合物的药物组合物。 公开了使用Btk抑制剂的方法，单独或与其它治疗剂组合用于治疗自身免疫性疾病或病症，异种免疫疾病或病症，癌症，包括淋巴瘤和炎性疾病或病症。

    INHIBITORS OF BRUTON'S TYROSINE KINASE
    10.
    发明申请
    INHIBITORS OF BRUTON'S TYROSINE KINASE 审中-公开
    BRUTON的酪氨酸激酶抑制剂

    公开(公告)号：US20140163027A1

    公开(公告)日：2014-06-12

    申请号：US14179457

    申请日：2014-02-12

    Applicant: Pharmacyclics, Inc.

    Inventor： Erik Verner ,  Wei Chen

    IPC: C07D487/04

    CPC classification number: C07D487/04 ,  A61K31/4985 ,  A61K31/519 ,  A61K45/06

    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

    Abstract translation: 本文描述的是不可逆激酶抑制剂化合物，用于合成这种不可逆抑制剂的方法，以及使用这种不可逆抑制剂治疗疾病的方法。 本文进一步描述了用于确定包括激酶在内的蛋白质的合适的不可逆抑制剂的方法，测定和系统。

Patent Agency Ranking